Search FDA's QSR Interpretation:     Advanced Search

 *** for more extensive look ---- Download our 328 page guide to Interpretation of FDA's QSR with QSIT Reference!

 

 

 

 

 

 

820.90 Nonconforming product.

 

(a) Control of nonconforming product. Each manufacturer shall establish and maintain procedures to control product that does not conform to specified requirements. The procedures shall address the identification, documentation, evaluation, segregation, and disposition of nonconforming product. The evaluation of nonconformance shall include a determination of the need for an investigation and notification of the persons or organizations responsible for the nonconformance. The evaluation and any investigation shall be documented.

(b) Nonconformity review and disposition. (1) Each manufacturer shall establish and maintain procedures that define the responsibility for review and the authority for the disposition of nonconforming product. The procedures shall set forth the review and disposition process. Disposition of nonconforming product shall be documented. Documentation shall include the justification for use of nonconforming product and the signature of the individual(s) authorizing the use.

(2) Each manufacturer shall establish and maintain procedures for rework, to include retesting and reevaluation of the nonconforming product after rework, to ensure that the product meets its current approved specifications. Rework and reevaluation activities, including a determination of any adverse effect from the rework upon the product, shall be documented in the DHR.

Interpretation:

The manufacturer shall establish and maintain procedures to control product that does not conform to specified requirements. These established procedures shall include identification, documentation, evaluation, segregation, and disposition of nonconforming product. The evaluation of product non-conformance shall include a determination of the need for an investigation and notification of the persons or organizations responsible for the nonconformance. This evaluation and any investigation shall be documented (820.90). The manufacturer shall establish procedures for identifying the training needs of personnel who handle nonconforming products in the course of their work. These people should be trained to recognize product noncomformance and take appropriate action to control nonconforming products including identifying product as nonconforming, documenting and evaluating the nonconformance, and segregating and disposing of nonconforming product. This training should be documented (820.25).

To facilitate detection of failure or defect trends, internal problem data, including service reports, and complaints should be arranged in a way that permits correlating present and past data for a particular product or product line. This can usually be achieved by organizing files according to product or product lines. Such data may be maintained in a computer file for quick accessibility and analysis.

The manufacturer shall establish and maintain procedures that define the responsibility for review and the authority for the disposition of nonconforming product. Nonconformance may occur in-house, as well as before product is distributed, along with nonconformances of distributed product. Procedures shall set forth the review and disposition process. Disposition of nonconforming product shall be documented. This documentation shall include the justification for any use of nonconforming product and the signature of individual(s) authorizing this use [820.90(b)(1)]. The decision to use a nonconforming product is usually done by a material review board (MRB). MRB boards should operate according to a written procedure and be comprised of individuals having the knowledge to determine suitability for use of nonconforming product.

Each manufacturer shall establish and maintain procedures for rework, including retesting and reevaluation of the nonconforming product after rework, to ensure that the product meets its current approved specifications. Rework and reevaluation activities, including the determination of any adverse effects from the product rework, shall be documented in the DHR [820.90(b)(2)].

 

 

 

 

 

 

Reference: www.FDA.gov

 

The information provided here is for "public consumption" and is open to interpretation. MedicalDeviceSchool.com is not responsible for the content or the accuracy of the information. For all official interpretation and accuracy we ask that you consult the FDA's website directly and that you consult with your legal and regulatory experts on all matters of interpretation.